Medical Adherence Consortium: MA-1 Paris May 6 & 7
Improving adherence through technology
A worldwide problem of striking magnitude (1)
Join industry leaders from the pharmaceutical, medical device, pharmacy, systems integrator, and health information handling sectors together with health care funders and regulators to jointly make progress in this complex area.
The consortium will help you accelerate your organisation’s activities related to improving medical adherence and ensure that you are well positioned to benefit from rapid changes relating to this topic.
A big problem. Poor medical adherence (also known as ‘medical compliance’) is recognised as one of the major challenges facing health care delivery in all countries of the world. The World Health Organisation has estimated adherence to chronic medication as being typically 50% (1). More recent studies (2) have demonstrated adherence rates as low as 25%.
Low adherence causes problems for all parts of the healthcare system: the purchasers who are paying for higher hospital readmission rates, the pharmaceutical industry through reduced use of their drugs, and the doctors and patients through poorer clinical outcomes. The problem has been estimated as costing $300bn per year (3).
A changing landscape. While not a new problem, the development of new technological approaches (‘Big Data’, ‘Internet of Things’, cheap sensors, mHealth and health apps) along with unprecedented cost pressures on the delivery of care mean that tackling poor medical adherence has gained new impetus.
The consortium approach. The size and complexity of the medical adherence problem makes it ideal for a multi-lateral consortium approach. This will enable participants to: identify and explore common themes and obstacles; where appropriate identify and disseminate best practice; and jointly remove some of the barriers inhibiting the use of technology to improve adherence and so health outcomes.
The consortium members include pharmaceutical companies, medical device providers, systems integrators, healthcare information handlers, private and public healthcare purchasers and providers, and leading academic experts in the field. The consortium is led by its industrial members and is international in scope – reflecting the geographical interest of the members but with an initial focus on Europe.
The goals of the consortium are defined by its members – its overall objective is to harness the capabilities and insights of its members to make substantive progress in this difficult area.
Participating organisations sign up to being consortium members for a year. The consortium is facilitated by CfBI using a tried and tested methodology. In all CfBI consortia, Chatham House rules are applied (discussions can be reported but not attributed) and there are no IP restrictions meaning that information exchange is rich, extensive, and immediately useful.
Programme of work
The areas where the consortium is initially focussing include:
· Economic / financial considerations: ensuring that good adherence makes economic sense for all actors.
· Standardisation: agreement around terminology, identification of gaps in information and other standards and planning to address these.
· Regulation: identification of key obstacles to improved adherence associated with regulation and determine the best way of engaging with the regulator to jointly determine if and how these might be changed.
· "Case studies": identification and dissemination of success stories to encourage wider engagement with the subject of adherence.
· Measurement / data: understanding problems around measurement of adherence, identifying and disseminating baseline measurements, agreeing standard approaches to measurement.
· Sustainability: ensuring that any adherence approaches are not only affordable but are sustainable for the long term.
Deliverables in each of these areas will include ‘baselining’ / gap analysis, awareness raising activities, the publishing of white papers / ‘position’ papers, the agreement and promulgation of ‘best practices’, and the working together to define pilot activities where appropriate.
What’s in it for me / my organisation?
· leverage the experience of other members rather than reinventing wheels;
· influence the creation of agreed (and influential) ‘consortium positions’ regarding various aspects of improving medical adherence;
· have a line of communication with funders/regulators: jointly influence regulatory and standards setting bodies;
· network with your peers from other industries: participate in a confidential and vendor neutral environment;
· link, inform and align the different strands of medical adherence activity within your organisation;
· get the inside view on problems and suppliers which are not talked about publically;
· be introduced to smaller players with novel and potentially disruptive technologies;
· share pilots or experiments (e.g., market and technology evaluations; pilots; supplier appraisal);
· use the ‘multiplier effect’ of the consortium to progress your agenda (subject to consortium agreement)design the consortium agenda, topics and content to ensure it satisfies your needs.
"Thank you for a fantastic inaugural event. We, at Bupa, at really looking forward to playing a full part in the Consortia’s activities to deliver the goals " Matt Bushell Director of Commissioning BUPA
For more information contact: email@example.com